Glycogenosis 2

10 registered clinical trials studyying Glycogenosis 2.

Status	Trial	Sponsor	Phase
Terminated	A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Pa NCT01597596	Genzyme, a Sanofi Company	Phase 4
Completed	Safety and Effectiveness Study of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respirato NCT00268944	Genzyme, a Sanofi Company	Phase 3
Completed	A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-O NCT00158600	Genzyme, a Sanofi Company	Phase 3
Completed	A Study of rhGAA in Patients With Late-Onset Pompe Disease NCT00250939	Genzyme, a Sanofi Company	Phase 2
Completed	Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-onset Pompe Disease NCT00074932	Genzyme, a Sanofi Company	N/A
Approved For Marketing	Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease NCT00074919	Genzyme, a Sanofi Company	—
Completed	rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease) NCT00053573	Genzyme, a Sanofi Company	Phase 1 / Phase 2
Completed	A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II NCT00051935	Genzyme, a Sanofi Company	Phase 2
Completed	Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe NCT00025896	Genzyme, a Sanofi Company	Phase 2
Approved For Marketing	Alglucosidase Alfa Temporary Access Program NCT00520143	Genzyme, a Sanofi Company	—